1. Younossi, Z. et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol.
Hepatol. 15, 11–20. https://doi.org/10.1038/nrgastro.2017.109 (2018).
2. Rinella, M. E. Nonalcoholic fatty liver disease: A systematic review. JAMA 313, 2263–2273. https://doi.org/10.1001/jama.2015.
5370 (2015).
3. Younossi, Z. M. Non-alcoholic fatty liver disease-a global public health perspective. J. Hepatol. 70, 531–544. https://doi.org/10.
1016/j.jhep.2018.10.033 (2019).
4. Polyzos, S. A., Kountouras, J. & Mantzoros, C. S. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.
Metabolism 92, 82–97. https://doi.org/10.1016/j.metabol.2018.11.014 (2019).
5. Younossi, Z. M. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and
meta-analysis. J. Hepatol. 71, 793–801. https://doi.org/10.1016/j.jhep.2019.06.021 (2019).
6. Marchesini, G. et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37, 917–923. https://doi.
org/10.1053/jhep.2003.50161 (2003).
7. Dulai, P. S. et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.
Hepatology 65, 1557–1565. https://doi.org/10.1002/hep.29085 (2017).
8. Adams, L. A. et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 129,
113–121. https://doi.org/10.1053/j.gastro.2005.04.014 (2005).
9. Tilg, H. & Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis.
Hepatology 52, 1836–1846. https://doi.org/10.1002/hep.24001 (2010).
10. Caligiuri, A., Gentilini, A. & Marra, F. Molecular pathogenesis of NASH. Int. J. Mol. Sci. https://doi.org/10.3390/ijms17091575
(2016).
11. Hosooka, T. et al. The PDK1-FoxO1 signaling in adipocytes controls systemic insulin sensitivity through the 5-lipoxygenaseleukotriene B(4) axis. Proc. Natl. Acad. Sci. USA 117, 11674–11684. https://doi.org/10.1073/pnas.1921015117 (2020).
12. Schuppan, D., Surabattula, R. & Wang, X. Y. Determinants of fibrosis progression and regression in NASH. J. Hepatol. 68, 238–250.
https://doi.org/10.1016/j.jhep.2017.11.012 (2018).
13. Hagstrom, H. et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven
NAFLD. J. Hepatol. 67, 1265–1273. https://doi.org/10.1016/j.jhep.2017.07.027 (2017).
14. Mederacke, I. et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology.
Nat. Commun. 4, 2823. https://doi.org/10.1038/ncomms3823 (2013).
15. Tsuchida, T. & Friedman, S. L. Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 14, 397–411. https://
doi.org/10.1038/nrgastro.2017.38 (2017).
16. Lehmann, J. M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor
gamma (PPAR gamma). J. Biol. Chem. 270, 12953–12956. https://doi.org/10.1074/jbc.270.22.12953 (1995).
17. Devchand, P. R., Liu, T., Altman, R. B., FitzGerald, G. A. & Schadt, E. E. The pioglitazone trek via human PPAR gamma: From
discovery to a medicine at the FDA and beyond. Front. Pharmacol. 9, 1093. https://doi.org/10.3389/fphar.2018.01093 (2018).
18. Aronoff, S. et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2
diabetes: A 6-month randomized placebo-controlled dose-response study. The pioglitazone 001 study group. Diabetes Care 23,
1605–1611. https://doi.org/10.2337/diacare.23.11.1605 (2000).
19. Dormandy, J. A. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study
(PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 366, 1279–1289. https://
doi.org/10.1016/S0140-6736(05)67528-9 (2005).
20. DeFronzo, R. A., Inzucchi, S., Abdul-Ghani, M. & Nissen, S. E. Pioglitazone: The forgotten, cost-effective cardioprotective drug
for type 2 diabetes. Diab. Vasc. Dis. Res. 16, 133–143. https://doi.org/10.1177/1479164118825376 (2019).
Scientific Reports |
(2023) 13:18983 |
https://doi.org/10.1038/s41598-023-46404-5
Vol.:(0123456789)
www.nature.com/scientificreports/
21. Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675–1685. https://doi.
org/10.1056/NEJMoa0907929 (2010).
22. Cusi, K. et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes
mellitus: A randomized trial. Ann. Intern. Med. 165, 305–315. https://doi.org/10.7326/M15-1774 (2016).
23. Mantovani, A., Byrne, C. D., Scorletti, E., Mantzoros, C. S. & Targher, G. Efficacy and safety of anti-hyperglycaemic drugs in
patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled
trials. Diabetes Metab. 46, 427–441. https://doi.org/10.1016/j.diabet.2019.12.007 (2020).
24. Belfort, R. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355,
2297–2307. https://doi.org/10.1056/NEJMoa060326 (2006).
25. Aithal, G. P. et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.
Gastroenterology 135, 1176–1184. https://doi.org/10.1053/j.gastro.2008.06.047 (2008).
26. Bell, L. N. et al. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: A pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up
study. Hepatology 56, 1311–1318. https://doi.org/10.1002/hep.25805 (2012).
27. Kawaguchi-Suzuki, M., Bril, F., Kalavalapalli, S., Cusi, K. & Frye, R. F. Concentration-dependent response to pioglitazone in
nonalcoholic steatohepatitis. Aliment. Pharmacol. Ther. 46, 56–61. https://doi.org/10.1111/apt.14111 (2017).
28. Kishino, S. et al. Polyunsaturated fatty acid saturation by gut lactic acid bacteria affecting host lipid composition. Proc. Natl. Acad.
Sci. USA 110, 17808–17813. https://doi.org/10.1073/pnas.1312937110 (2013).
29. Colas, R. A., Shinohara, M., Dalli, J., Chiang, N. & Serhan, C. N. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am. J. Physiol. Cell Physiol. 307, C39-54. https://d
oi.o
rg/1 0.1 152/a jpcel l.0 0024.2 014 (2014).
30. Hosooka, T. et al. Dok1 mediates high-fat diet-induced adipocyte hypertrophy and obesity through modulation of PPAR-gamma
phosphorylation. Nat. Med. 14, 188–193. https://doi.org/10.1038/nm1706 (2008).
31. Tsukada, S., Parsons, C. J. & Rippe, R. A. Mechanisms of liver fibrosis. Clin. Chim. Acta 364, 33–60. https://doi.org/10.1016/j.cca.
2005.06.014 (2006).
32. Parola, M. & Pinzani, M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol. Aspects Med. 65, 37–55.
https://doi.org/10.1016/j.mam.2018.09.002 (2019).
33. Clapper, J. R. et al. Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease
progression and methods of assessment. Am. J. Physiol. Gastrointest. Liver Physiol. 305, G483-495. https://doi.org/10.1152/ajpgi.
00079.2013 (2013).
34. Lefebvre, P. et al. Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARalpha-regulated
dermatopontin. JCI Insight https://doi.org/10.1172/jci.insight.92264 (2017).
35. Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic
fatty liver disease. Gastroenterology 149, 389–397. https://doi.org/10.1053/j.gastro.2015.04.043 (2015).
36. Suckow, A. T. et al. Alteration of the glucagon axis in GPR120 (FFAR4) knockout mice: A role for GPR120 in glucagon secretion.
J. Biol. Chem. 289, 15751–15763. https://doi.org/10.1074/jbc.M114.568683 (2014).
37. Miyamoto, J. et al. Gut microbiota confers host resistance to obesity by metabolizing dietary polyunsaturated fatty acids. Nat.
Commun. 10, 4007. https://doi.org/10.1038/s41467-019-11978-0 (2019).
38. Bluher, M. Metabolically healthy obesity. Endocr. Rev. 41, bnaa004. https://doi.org/10.1210/endrev/bnaa004 (2020).
39. Kloting, N. et al. Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab. 299, E506-515. https://d
oi.o
rg/1 0.1 152/a jpend
o.0 0586.
2009 (2010).
40. Goto, T. et al. 10-oxo-12(Z)-octadecenoic acid, a linoleic acid metabolite produced by gut lactic acid bacteria, potently activates
PPARgamma and stimulates adipogenesis. Biochem. Biophys. Res. Commun. 459, 597–603. https://doi.org/10.1016/j.bbrc.2015.
02.154 (2015).
41. Spiegelman, B. M. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 47, 507–514. https://doi.org/10.
2337/diabetes.47.4.507 (1998).
42. Okuno, A. et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese
Zucker rats. J. Clin. Invest. 101, 1354–1361. https://doi.org/10.1172/JCI1235 (1998).
43. Miyazaki, Y. et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J.
Clin. Endocrinol. Metab. 89, 4312–4319. https://doi.org/10.1210/jc.2004-0190 (2004).
44. Miyazawa, M. et al. Pioglitazone inhibits periprostatic white adipose tissue inflammation in obese mice. Cancer Prev. Res. (Phila)
11, 215–226. https://doi.org/10.1158/1940-6207.CAPR-17-0296 (2018).
45. Dubuquoy, L. et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 55, 1341–1349. https://doi.org/
10.1136/gut.2006.093484 (2006).
46. Christofides, A., Konstantinidou, E., Jani, C. & Boussiotis, V. A. The role of peroxisome proliferator-activated receptors (PPAR)
in immune responses. Metabolism 114, 154338. https://doi.org/10.1016/j.metabol.2020.154338 (2021).
47. Huang, Y. et al. Pioglitazone attenuates experimental colitis-associated hyperalgesia through improving the intestinal barrier
dysfunction. Inflammation 43, 568–578. https://doi.org/10.1007/s10753-019-01138-3 (2020).
48. Schaefer, K. L. et al. Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma
ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm. Bowel Dis. 11, 244–252.
https://doi.org/10.1097/01.mib.0000160770.94199.9b (2005).
Acknowledgements
This work was supported, in part, by Japan Society for the Promotion of Science KAKENHI grants (21H03355
to TH). We thank C. Aoki (Kobe University) and K. Sato (University of Shizuoka) for assistance with mouse
experiments.
Author contributions
T.H. designed research; N.K., Y.I., R.A., M.S., K.O., Y.H., M.I., C.T., J.K., S.K., J.O., W.O., and T.H. performed
research; N.K., Y.I., R.A., M.S., K.O., Y.H., M.I., C.T., J.K., S.K., J.O., W.O., and T.H. analyzed data; Y.I., and T.H.
wrote the paper.
Competing interests The authors declare no competing interests.
Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/
10.1038/s41598-023-46404-5.
Scientific Reports |
Vol:.(1234567890)
(2023) 13:18983 |
https://doi.org/10.1038/s41598-023-46404-5
10
www.nature.com/scientificreports/
Correspondence and requests for materials should be addressed to T.H.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2023
Scientific Reports |
(2023) 13:18983 |
https://doi.org/10.1038/s41598-023-46404-5
11
Vol.:(0123456789)
...
論文の公開元へ
